Adding radium-223 to estrogen therapy to target bone metastases may provide slight gain but comes with more adverse events. The study was published as a preprint and has not yet been peer reviewed.
First Look
Adding radium-223 to estrogen therapy to target bone metastases may provide slight gain but comes with more adverse events. The study was published as a preprint and has not yet been peer reviewed.
First Look
